Breast cancer is the most common and lethal cancer type in women worldwide with increasing occurrence and mortality rates. Breast carcinoma, specifically, accounts for almost 25% of all cancers in women with more than 50,000 cancer cases to be diagnosed in the UK each year and 1.37 million new cases over the world. Breast tumours are characterised by heterogeneity in the molecular profile and therefore tumour progression behaviour, with predominant the triple-negative types, the progesterone receptor dependent types [PgR]), the steroid hormone receptor dependent types (oestrogen receptor [ER]), and the overexpressing human epidermal growth factor receptor-2 (HER2) positive subgroups, which account for 15-20% of cases. The development of smart therapeutic nanodrug systems targeting breast malignancies has been the subject of pharmaceutical study since the late 1980s, with liposomes to be so far the most well studied drug delivery system. Liposomes can target efficiently the breast tumours either passively by taking advantage the EPR effect or actively through receptor-mediated endocytosis. In this project, the manufacturing process of PEGDOX liposomes targeting highly metastatic breast cancer cells consists the overall aim of the study. Two different preparative methods were evaluated in order to prepare liposomes with a controlled and homogeneous size (
- liposomes, drug delivery, microfluidics, thin-film hydration, breast cancer, doxorubicin, coumarins, pentapeptide
Manufacturing steps towards standard and highly reproducible liposomes for advanced drug delivery to breast cancer cells
Gkionis, L. (Author). 1 Aug 2020
Student thesis: Phd